Cinnagen

Cinnagen company information, Employees & Contact Information

Explore related pages

Related company profiles:

CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.

Company Details

Employees
540
Founded
-
Address
No. 34, Sepehr Street, Farahzadi Blvd,shahrak Gharb, Tehran,tehran,iran, Islamic Republic Of
Phone
+98 21 42815
Email
ci****@****gen.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
tehran, tehran
Looking for a particular Cinnagen employee's phone or email?

Cinnagen Questions

News

Transforming healthcare: CinnaGen’s leadership in follow-on biologicals/ biosimilars development and market expansion - Generics and Biosimilars Initiative

Transforming healthcare: CinnaGen’s leadership in follow-on biologicals/ biosimilars development and market expansion Generics and Biosimilars Initiative

Design, Synthesis, in Vitro, and in Silico Evaluation of N‐Phenylacetamide‐Oxindole‐Thiosemicarbazide Hybrids as New Potential Tyrosinase Inhibitors - Yari Boroujeni - 2022 - Chemistry & Biodiversity - Wiley Online Library

Design, Synthesis, in Vitro, and in Silico Evaluation of N‐Phenylacetamide‐Oxindole‐Thiosemicarbazide Hybrids as New Potential Tyrosinase Inhibitors - Yari Boroujeni - 2022 - Chemistry & Biodiversity Wiley Online Library

CinnaGen CEO not holding back in ambition to be a global player - The Pharma Letter

CinnaGen CEO not holding back in ambition to be a global player The Pharma Letter

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product - Generics and Biosimilars Initiative

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product Generics and Biosimilars Initiative

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar - Fierce Pharma

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar Fierce Pharma

Iran opens biopharmaceutical factory in Turkey - Tehran Times

Iran opens biopharmaceutical factory in Turkey Tehran Times

The journey of Pectuna pertuzumab follow-on biological in Iran - Generics and Biosimilars Initiative

The journey of Pectuna pertuzumab follow-on biological in Iran Generics and Biosimilars Initiative

Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma - Generics and Biosimilars Initiative

Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma Generics and Biosimilars Initiative

MENA region biologicals maker CinnaGen receives EU GMP certification - Generics and Biosimilars Initiative

MENA region biologicals maker CinnaGen receives EU GMP certification Generics and Biosimilars Initiative

MENA mAb manufacturer AryoGen receives EU GMP approval - Generics and Biosimilars Initiative

MENA mAb manufacturer AryoGen receives EU GMP approval Generics and Biosimilars Initiative

CinnaGen to invest in Turkish pharmaceuticals sector - Generics and Biosimilars Initiative

CinnaGen to invest in Turkish pharmaceuticals sector Generics and Biosimilars Initiative

Top Cinnagen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant